Michel de Weers

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer et al. · The Journal of Immunology · 2010 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren, Danielle Jakobs, Niels Kaldenhoven et al. · Blood · 2014 · 221 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica · 2010 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages

Michel de Weers, Martie C. M. Verschuren, Margriet E. M. Kraakman et al. · European Journal of Immunology · 1993 · 205 citations

Life Sciences, Genetics, Molecular Biology +17

B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.

Michel de Weers, Gaby Brouns, Steve Hinshelwood et al. · Journal of Biological Chemistry · 1994 · 183 citations · Full text

Life Sciences, Immunology, Molecular Biology +17